Skip to content
Popular Searches
  • # Cancer
  • # FDA
  • # Alzheimer's
  • # Hoffmann-La Roche
  • # FDA Approval
  • # DNA
  • linkedin
  • facebook
  • instagram
  • twitter
  • youtube
Home BiotechReality – Covering Industry, Business, and Academia

Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.

  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
Trending

Trending

Roche’s Supplemental Biologics License Application of Gazyva/Gazyvaro (Obinutuzumab) for The Treatment of Lupus Nephritis Accepted by U.S. FDA

6 March 2025

Risk of Alzheimer’s can be reduced by popular diabetes and weight-loss drug

26 October 2024

CRISPR gene editing trials for vision show rapid improvement

14 May 2024

JN.1 New COVID-19 variant: Spreading rapidly

23 December 2023

Research Finds Out How Location Influences Immune System’s Ability to Fight Disease, Supports Vaccines and Immunotherapy

29 January 2025

Deep learning develops proteins that protect against the venom of deadly snakes

16 January 2025

Escherichia coli or E. coli – Structure and Function

16 May 2024

Genomics Research Can be Automated by Artificial Intelligence

3 December 2024

Meiosis: Definition, Stages, Mechanism, and Diagram

26 February 2024

US FDA Approves Ctexli, First Treatment for Cerebrotendinous Xanthomatosis of Mirum Pharma

22 February 2025

Electron Microscopy – Specimen Preparation, Types, and Application

21 September 2023

Merck Announces Positive Results of Phase 3 Trials for Their HIV-1 Investigational Two-Drug Regimen Doravirine/Islatravir

13 March 2025

AstraZeneca

AstraZeneca’s Datroway Receives US Approval for EGFR-Mutated Lung Cancer
News Oncology Regulatory Approval

AstraZeneca’s Datroway Receives US Approval for EGFR-Mutated Lung Cancer

Ajmal Aseem 25 June 2025

AstraZeneca’s Datroway has received US FDA approval for advanced EGFR-mutated lung cancer. This first-in-class TROP2-directed therapy offers a vital new option for patients who have exhausted previous treatments.

AstraZeneca Secures EU’s Approval for Fixed-Duration Calquence-Based Regimens in First-Line Chronic Lymphocytic Leukemia (CLL)
Healthcare & Pharmaceuticals News Regulatory Approval

AstraZeneca Secures EU’s Approval for Fixed-Duration Calquence-Based Regimens in First-Line Chronic Lymphocytic Leukemia (CLL)

Athulya B S 7 June 2025

AstraZeneca’s Calquence-based fixed-duration regimens gain EU approval for treating first-line CLL, offering patients a powerful, time-limited alternative to traditional continuous therapy.

AstraZeneca’s Imfinzi® Demonstrates Significant Improvement in Disease-Free Survival for Early-Stage Bladder Cancer Patients
Clinical Trials Healthcare & Pharmaceuticals News

AstraZeneca’s Imfinzi® Demonstrates Significant Improvement in Disease-Free Survival for Early-Stage Bladder Cancer Patients

Ajmal Aseem 10 May 2025

The Phase III POTOMAC trial evaluated the effectiveness of Imfinzi in combination with BCG therapy compared to BCG therapy alone in patients with high-risk NMIBC.

AstraZeneca Released KALOS and LOGOS Phase III Clinical Trials Result Shows Positive High-level Results of Breztri for Treating Asthma
Clinical Trials Healthcare & Pharmaceuticals News

AstraZeneca Released KALOS and LOGOS Phase III Clinical Trials Result Shows Positive High-level Results of Breztri for Treating Asthma

Athulya B S 2 May 2025

The purpose of the duplicate, randomized, double-blind KALOS and LOGOS trials was to examine Breztri as a possible asthma medication.

AstraZeneca Released Satisfactory Results of 24 Weeks CALYPSO Phase III Trial for Eneboparatide
Clinical Trials Healthcare & Pharmaceuticals News

AstraZeneca Released Satisfactory Results of 24 Weeks CALYPSO Phase III Trial for Eneboparatide

Editor's Desk 17 March 2025

Trial continues as planned to 52 weeks to further characterize the risk-benefit profile.

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • Cell Biology
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Life Sciences
  • Machine Learning
  • Medical Devices
  • Mental Health
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs
Market Analysis
Publish on BiotechReality

  • Cytiva Hiring a Quality Control Technician in Cardiff, United Kingdom
  • PhD Position in Dialysis Therapy – University of Twente, Netherlands
  • Eli Lilly and Company Hiring a Analytical Technical Steward-Peptides in Hyderabad, India – June, 2025
  • ICON Hiring a Clinical Data Programming Lead in Chennai, India
  • PhD Position in Food Biotechnology – University of Reading, United Kingdom
SciRealityPress BiotechReality

A SciRealityPress Associate

DMCA.com Protection Status

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2025
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinuePrivacy policy